You're replying to a post I made in 2013 about AMRN, ARNA, and VVUS - WTF? Two of those 3 no longer exist - VVUS went BK, and PFE bought ARNA last year for $100/shr for another drug in their pipeline that had excellent P2 results*** - my 11 yr wait finally paid off, my basis was $40 and I owned a boatload of it in 3 accounts - about the same I have invested in AMRN, but I have zero hope of a similar outcome occurring because of problems everyone here is aware of. I'd love to get at least half the money back that I put in AMRN (pps $3.25), but even that is a stretch at this point - maybe in a couple years when EU and China sales actually amount to real income for AMRN. HLS royalties from sales in Canada are stuck at around $2M/yr, several years after V was approved there.
*** The weight loss drug I bought ARNA for, Belviq, was pulled from the market by FDA over cancer concerns after people had been taking it for years (not many people, sales were terrible and ARNA sold the rights to Easai). What's concerning in this case is ARNA originally got a CRL over tumor concerns in a study they did on rats - they re-examined the data, waved their hands over it, said everything was fine, FDA accepted it, and then later discovered the Adcom's breast cancer worries were real and they should not have approved the drug.
News 
Market Data 
Discover 
